Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hope in action: peer support may curb suicide risk in youth facing psychosis

NCT ID NCT07756567

Symptom relief Sponsor: University of California, San Diego Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 10, 2026 · Last updated Aug 13, 2026 · Updated 3 times

Summary

This study tests a new group program designed for young people at clinical high risk for psychosis who also have suicidal thoughts or behaviors. The program, led by a clinician and a peer with lived experience, focuses on building hope, setting recovery goals, and strengthening social connections. Caregivers join a session to learn how to support their young person. Researchers will compare the program plus standard care to standard care alone to see if it improves personal recovery and helps participants remember and use suicide prevention strategies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A recovery-oriented suicide prevention group program led by a clinician and a peer specialist with lived experience, added to standard care.
What this could lead to
If successful, this program could offer a new way to reduce suicide risk and support personal recovery in young people at high risk for psychosis.
What could go wrong
The trial is still in development and testing, so the program may not prove more effective than standard care alone. Participation requires a caregiver, which may limit who can join.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 108 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 30 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Young Person Inclusion Criteria: * symptoms of clinical high risk for psychosis in the last two years * lifetime active suicide ideation and/or lifetime suicide behavior * has a caregiver willing to participate Young Person Exclusion Criterion: * not able to read and write in English Caregiver Inclusion Criteria: * has a familial relationship with the young person participant * has at least 4 hours of face-to-face contact with the patient participant every week, even if they do not live together Caregiver Exclusion Criteria: None \*\*\* Administrator/Clinician Inclusion Criteria: * employed at the University of California, San Diego or University of California, Los Angeles early psychosis program Administrator/Clinician Exclusion Criteria: None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Clinical high risk for psychosis (CHR) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psychotic disorder Psychotic Disorders Suicidal Ideation Suicide

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Clinical high risk for psychosis (CHR) Psychosis Suicidal behavior Suicidal ideation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of California, Los Angeles

    Los Angeles, California, 90095, United States

  • University of California, San Diego

    San Diego, California, 92161, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.